[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Auckland, New Zealand\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":369},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,72,115,143,174,205,233,263,285,318,339],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100581731","prokinetics-and-body-surface-gastric-mapping-in-dyspeptic-patients-baseline-and-treatment-effects-100581731",false,"NCT06854120","Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects","Body Surface Gastric Mapping in Patients With Dyspeptic Symptoms: Recordings at Baseline and on Medical Therapy","Inclusion Criteria:\n\n* Patients 18 years of age and older\n* Diagnosis of gastroparesis and\u002For functional dyspepsia\n* Being prescribed a prokinetic agent or symptom modulator for their clinical care\n* Able to undergo BSGM recording both before and during treatment\n* Able to give informed consent for undergoing a baseline BSGM recording and an additional recording while on treatment\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Prior surgery on esophagus, stomach (appendectomy and cholecystectomy are allowed)\n* History of skin allergies or a history of extreme sensitivity to cosmetics or lotions\n* Pregnant women\n* No vulnerable groups such as prisoners, individuals with known cognitive impairment, or institutionalized individuals be involved","ALL","18 Years",{"count":19,"type":20},125,"ESTIMATED","OBSERVATIONAL","Functional dyspepsia and gastroparesis are common stomach disorders with symptoms like early satiety, nausea, and abdominal pain, and are often evaluated with gastric emptying tests, although the correlation with symptoms is weak. Prokinetic agents (e.g., metoclopramide, erythromycin) and symptom modulators (e.g., nortriptyline, mirtazapine) are commonly used, but selecting the right medication can be difficult, as it's often based on symptoms rather than the underlying gastric issues. Body Surface Gastric Mapping (BSGM) using the Gastric Alimetry device is a novel, non-invasive tool to assess gastric myoelectrical activity and symptoms. This study aims to perform two BSGM recordings-one before and one after medical therapy-to understand how medications affect gastric function and identify baseline BSGM factors that could predict responses to treatment, potentially guiding tailored therapies based on individual gastric dysfunction.",[24,25],"Gastroparesis","Functional Dyspepsia",[24,25,27,28],"Gastric Motility","Body Surface Gastric Mapping","RECRUITING","2026-06-08",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":33},"2025-02-26",{"date":37,"type":20},"2028-08-26",{"name":39,"class":40},"University of Auckland, New Zealand","OTHER",3,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100633111","the-effects-of-open-label-placebos-on-acute-stress-100633111","NCT07522437","The Effects of Open-label Placebos on Acute Stress","Inclusion Criteria:\n\n* Signed-up to complete the canyon swing\n* Aged 18 years and over\n* Able to speak and understand English\n* Comfortable being randomised to either the open-label placebo or no-treatment control condition\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Unable to speak or understand English\n* Unable to provide informed consent",true,{"count":50,"type":20},260,"INTERVENTIONAL",[53],"NA","The goal of this study is to find out whether an open-label placebo nasal spray can reduce stress among individuals engaging in a high-stress canyon swing. The main questions the study aims to answer are: 1) Does an open-label placebo increase likelihood of participants completing another jump? 2) Does the placebo affect how long it takes participants to jump, reduce the reported stress levels before the jump 3) Does the placebo change how enjoyable participants find the jump?\n\nResearchers will compare participants who receive an open-label placebo nasal spray (a spray that contains no active medication and is clearly described as a placebo) with participants who receive no treatment (control). The aim is to see whether the placebo nasal spray can increase likelihood of participants completing another jump, reduce reported stress and improve participants overall enjoyment of the jump.\n\nParticipants will:\n\n* Complete a short questionnaire before they jump\n* Either self administer a placebo nasal spray (one spray in each nostril) right before stepping through the gate to jump, or receive no treatment (control).\n* Complete a short questionnaire after completing the jump\n* Whether they complete another jump will be noted",[56,57],"Acute Stress","Stress",[59,60,61],"Open label placebo","Acute stress","Canyon Swing","NOT_YET_RECRUITING","2026-04-09",{"date":65,"type":33},"2026-04-13",{"date":67,"type":20},"2026-04",{"date":69,"type":20},"2026-11",{"name":39,"class":40},1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":51,"phases":82,"briefSummary":83,"conditions":84,"keywords":95,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":71},"100579954","assessing-the-effect-of-cool-roofs-on-health-using-smartwatches-in-colima-mexico-100579954","NCT06831006","Assessing the Effect of Cool Roofs on Health Using Smartwatches in Colima, Mexico","A Randomized Controlled Trial (RCT) Evaluating the Effects of Cool Roofs on Health Outcomes Using Smartwatches in Colima, Mexico","REFLECT","Inclusion Criteria:\n\n* Permanent household resident\n\nExclusion Criteria:\n\n* Roof damage, inaccessible or instability of roof adversely affecting cool roof coating application.\n* Participant unable to provide written\u002Fverbal informed consent. Participants will be excluded if they are not willing or able to wear a smartwatch.\n* Participants will be excluded if they do not have a smartphone with an internet connection that can connect to the smartwatch.\n* Only one participant per household.",{"count":81,"type":20},800,[53],"Ambient air temperatures in Mexico have broken record highs in 2024. Solutions are needed to build heat resilience in communities and adapt to increasing heat from climate change. Sunlight-reflecting cool roof coatings may passively reduce indoor temperatures and energy use to protect home occupants from extreme heat. Occupants living in poor housing conditions in the northern zone of Mexico are susceptible to increased heat exposure.\n\nHeat exposure can instigate and worsen numerous physical, mental and social health conditions. The worst adverse health effects are experienced in communities that are least able to adapt to heat exposure. By reducing indoor temperatures, cool roof use may promote heart health, sleep and physical activity in household occupants.\n\nThe long-term research goal of the investigators is to identify viable passive housing adaptation technologies with proven health benefits to reduce the burden of heat stress in communities affected by heat in Mexico. To meet this goal, the investigators will conduct a randomized controlled trial to establish the effects of cool roof use on heart rate, sleep and physical activity in Colima, Mexico.",[85,86,87,88,89,90,91,92,93,94],"Heart Rate","All-day Steps","Distance Walked","Active Minutes","Moderate-intensity Activity Minutes","Vigorous-intensity Activity Duration","Sleep Quantity","Time in Sleep Stages","Awake Duration","Sleep Score",[96,97,98,99,100,101,102,103,104,105,106],"Hot Temperature","Humidity","Housing","Wearable","Smartwatch","Heart rate","Cardiovascular","Physical activity","Sleep","Cool roof","Heat stress","2026-03-09",{"date":109,"type":33},"2026-03-11",{"date":111,"type":20},"2026-04-01",{"date":113,"type":20},"2027-09-01",{"name":39,"class":40},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":51,"phases":125,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100624106","a-brief-video-intervention-to-improve-patient-outcomes-following-radioiodine-treatment-100624106","NCT07405320","A Brief Video Intervention to Improve Patient Outcomes Following Radioiodine Treatment","Testing a Brief Video Intervention to Support Patient Coping Following Radioiodine Treatment","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Clinical diagnosis of hyperthyroidism or thyroid cancer\n* Scheduled to receive radioiodine therapy at Auckland City Hospital Radiation Oncology Clinic\n* Able to understand and communicate in English\n* Access to an internet-connected device to complete study questionnaires\n\nExclusion Criteria:\n\n* Completed previous radioiodine treatment\n* Self-reported difficulty completing questionnaires","75 Years",{"count":124,"type":20},80,[53],"This study will test the impact of a short video intervention for people who are receiving radioiodine treatment for thyroid conditions (such as hyperthyroidism or thyroid cancer). After their single-dose treatment, patients need to follow safety instructions to protect others and manage side effects during recovery. Some people find these instructions hard to remember, and side effects (or anticipation of side effects) can feel worrying or disruptive. The video aims to present the treatment information in a more accessible patient-friendly way, so that patients feel less distressed, find their side effects easier to cope with, and better engage with safety precautions. All patients will first have a pre-treatment consultation with their doctor and receive the standard treatment information currently provided. Before this consultation patients will be randomly assigned to view one of two videos. The control group will see a neutral video that details standard health information that is not specific to radioiodine, while the intervention group will see a video that explains side effects, safety requirements and recovery period in a more adaptive way. Comparing these two groups will allow us to assess whether this new approach improves coping, reduces distress, and enhances adherence to safety instructions in the post-dose recovery phase of radioiodine treatment.",[128,129,130],"Thyroid Cancer","Hyperthyroidism","Radioiodine Treatment",[132,133,134],"Mindset","Digital Intervention","Radioiodine","2026-02-04",{"date":137,"type":33},"2026-02-12",{"date":139,"type":20},"2026-01-12",{"date":141,"type":20},"2026-07-06",{"name":39,"class":40},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":48,"sex":16,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":153,"conditions":154,"keywords":161,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100618878","co-development-and-validation-of-colonic-symptom-pictograms-for-young-people-100618878","NCT07337343","Co-Development and Validation of Colonic Symptom Pictograms for Young People","Inclusion Criteria:\n\nChildren and Young people are aged between 8-17 years,\n\n* have lower gut or constipation symptoms,\n* can communicate in English or be supported to participate by a caregiver, whānau, or other responsible person. Phase Four will include international invitations to participants with lower gut or constipation symptoms. Healthy volunteers will not be recruited.\n\nExclusion Criteria:\n\n* Children and Young people with developmental or cognitive disorder that precludes their ability to understand the study,\n* Children and Young people who do not have access to a digital device with internet connectivity,\n* unable to read English,\n* parent does not consent","8 Years","17 Years",{"count":152,"type":20},120,"Severe constipation affects 10% of children, often leading to significant physical and emotional distress. While constipation is commonly associated with impaired bowel movements, it is fundamentally linked to abnormalities in colonic motility - the coordinated contractions that facilitate passage of stool through the colon and out of the body. Diagnosis of constipation is based upon the Rome IV criteria, which assess symptoms as reported or remembered over the previous 3 months.\n\nHowever, reporting symptoms experienced can be challenging for children and young people for many reasons, such as the overlap of sensations, including fullness, bloating, and discomfort, and an inability to recall or precisely distinguish and describe what they are feeling.\n\nThis study intends to design, develop, and validate symptom pictograms for children aged 8-17 with colonic or lower gut symptoms.",[155,156,157,158,159,160],"Constipation - Functional","Abdominal Pain (AP)","Nausea and Vomitting","Bloating","Flatulence","IBS, Constipation Predominant",[162,163,164,165],"children and adolescents","pictograms","co-design","validation","2026-01-02",{"date":168,"type":33},"2026-01-13",{"date":170,"type":20},"2026-01-01",{"date":172,"type":20},"2027-04-01",{"name":39,"class":40},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":51,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":71},"100594293","views-on-information-resources-for-kidney-transplantation-patients-100594293","NCT07017556","Views on Information Resources for Kidney Transplantation Patients","An Exploratory Mixed-Methods Pilot Study on the Use of Educational Videos to Improve Knowledge and Satisfaction in Kidney Transplantation Patients","Inclusion Criteria:\n\n* Pre-transplant patients are on the kidney transplant wait list\n* Post-transplant patients have received a transplant within the last 12 months.\n* Participants are 18 years or over.\n* Participants can read and understand English.\n* Participants are located within the Auckland Metro region.\n\nExclusion Criteria:\n\n* Any impairments preventing informed consent.",{"count":182,"type":20},60,[53],"The goal of this pilot study is to find out whether educational videos can help patients better understand, and remember, important information regarding the benefits and risks of having a kidney transplant.\n\nThe study aims to answer several questions, including:\n\n1. Is the video-based educational intervention acceptable and feasible for kidney transplant patients?\n2. Does the intervention improve patient knowledge and satisfaction immediately after viewing?\n3. Does the intervention improve patient knowledge retention a week later?\n4. What are patients views on the video format as an educational tool?\n\nAt the moment, patients learn about kidney transplantation through written documents, and discussions and conversations with their clinicians \u002F doctors. However, the concern here is that not everyone has the same level of understanding when it comes to language literacy, medical jargon and information. This can result in gaps in knowledge, misunderstandings, and \u002F or misinterpretations, including the need for lifelong medication and possible post-transplant complications.\n\nPatients understanding of the benefits and risks of transplantation is extremely important, as there are aspects which patients may not be aware of, including the need for (and importance of) lifelong medication, and also potential disease complications which may follow transplantation. For example, following a kidney transplant, it is not uncommon for patients to develop diabetes.\n\nParticipants in the study will:\n\nWatch two short videos (roughly five minutes each) that explain the benefits and risks of kidney transplantation.\n\nAnswer some questions before video viewing, immediately after video viewing, and one week after video viewing.\n\nComplete a short interview to give deeper feedback on the videos.\n\nThis study will explore whether using video helps patients to feel more informed and also satisfied with the clinical information they receive, and whether they can better retain this information. The investigators aim to support more informed patients, making transplant education clearer, more accessible, and generally easier to understand.",[186],"End-Stage Renal Disease",[188,189,190,191,192,193,194,195,196],"mixed-methods","pilot study","education","end-stage renal disease","kidney transplantation","feasibility study","repeated measures","video-based education","kidney disease","2025-06-11",{"date":199,"type":33},"2025-06-15",{"date":201,"type":20},"2025-06",{"date":203,"type":20},"2026-02",{"name":39,"class":40},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":51,"phases":214,"briefSummary":215,"conditions":216,"keywords":220,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":71},"100590799","digital-mindset-intervention-for-half-marathon-performance-100590799","NCT06972121","Digital Mindset Intervention for Half Marathon Performance","The Efficacy of a Digital Mindset Intervention to Improve Race Performance, Training Outcomes, and Recovery in Recreational Half Marathon Runners: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Be aged 18 years or older\n* Be registered to run (not walk) in a 2025 half marathon in New Zealand\n* Be running their 1st, 2nd, or 3rd half marathon\n* Be able to complete the half-marathon without physical assistance or aids\n* Be able to read and understand English\n* Have regular access to email or an internet-connected device\n\nExclusion Criteria:\n\n* Have completed more than 2 half marathons in the past\n* Are currently injured or unable to complete the race unassisted\n* Are unable to complete online questionnaires independently\n* Do not have access to a device capable of receiving digital content via app or email",{"count":213,"type":20},207,[53],"The goal of this randomized controlled trial is to test whether a brief digital mindset training program can improve performance among recreational runners training for a half marathon in New Zealand in 2025. The study will recruit healthy adult participants who are registered for an upcoming half-marathon event.\n\nThe study aims to answer two main questions:\n\n1. Does the mindset training program - designed to reframe common physical symptoms like fatigue or muscle soreness as signs of progress - help more runners complete the race and improve their official times, compared to standard training advice?\n2. Does it support better training (e.g., longer peak training weeks) and faster physical recovery after the race?\n\nResearchers will compare participants who receive the mindset training program to those who receive widely followed half-marathon training content and a group who receive no study content, to see whether the mindset training leads to better half-marathon performance and training outcomes.\n\nParticipants will:\n\n* Complete a brief online survey at the start of the study\n* Receive and engage with four pieces of digital content across nine weeks before the half-marathon race (if assigned to a training group)\n* Complete a follow-up survey after the half-marathon",[217,218,219],"Healthy","Exercise","Psychological Intervention",[132,218,221,222,223,224],"Physical Activity","Sports psychology","Marathon","Performance","2025-05-21",{"date":227,"type":33},"2025-05-28",{"date":229,"type":33},"2025-05-15",{"date":231,"type":20},"2025-09",{"name":39,"class":40},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":51,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":71},"100591021","comparing-the-stress-reducing-effects-of-a-robotic-pet-and-a-weighted-toy-100591021","NCT06975007","Comparing the Stress-Reducing Effects of a Robotic Pet and a Weighted Toy","Comparing the Stress-Reducing Effects of a Robotic Pet and a Weighted Toy: A Randomised Experimental Study","Inclusion Criteria:\n\n* over 18 years old\n* fluent in English\n* free from diagnosed anxiety or stress-related disorders\n\nExclusion Criteria:\n\n* cardiovascular conditions that may affect heart rate and blood pressure measurements\n* existing anxiety disorders or panic disorders.",{"count":241,"type":20},51,[53],"The goal of this trial is to learn whether interacting with a robotic pet (Paro) or holding a weighted sensory toy can reduce stress in healthy adults after an acute stressful experience. The main questions it aims to answer are:\n\n* Does interacting with Paro or holding a weighted toy lower self-reported stress and anxiety levels?\n* Does interacting with Paro or holding a weighted toy lower physiological markers of stress, such as heart rate and blood pressure?\n\nResearchers will compare interaction with Paro (robotic pet), interaction with a weighted sensory toy and a control group with no intervention to see which method is most effective in reducing stress.\n\nParticipants will:\n\n1. Complete a stress induction task (Trier Social Stress Test);\n2. Be randomly assigned to interact with Paro, hold a weighted toy, or sit quietly without intervention;\n3. Have their heart rate and blood pressure measured;\n4. Complete surveys about their stress, anxiety and mood before and after the intervention.",[57],[246,247,248,249,250,60,251,101,252,253,254],"Stress reduction","Robotic pet","Paro","Weighted sensory toy","Deep pressure stimulation","Trier Social Stress Test (TSST)","Blood pressure","Human-robot interaction","Sensory modulation","2025-05-07",{"date":257,"type":33},"2025-05-16",{"date":259,"type":20},"2025-05",{"date":261,"type":20},"2025-10",{"name":39,"class":40},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":51,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":284},"100528568","feasibility-trial-of-eus-pca-in-ipmn-pancreatic-cysts-100528568","NCT06162468","Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts","Single-arm Intervention Trial of the Feasibility of Endoscopic Ultrasound-guided Pancreatic Cyst Chemoablation (EUS-PCA) Using Gemcitabine and Paclitaxel for Intraductal Papillary Mucinous Neoplasms (IPMN) in Two New Zealand Tertiary Interventional Endoscopy Centres","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Radiological diagnosis of branch duct IPMN.\n* Cyst size of 3cm or worrying growth on serial imaging.\n* Suitable to undergo endoscopy under deep sedation or general anaesthesia.\n* Willing and able to comply with all trial requirements, including treatment, timing and\u002For nature of required assessments.\n* Signed, written informed consent.\n\nExclusion Criteria:\n\n* Presence of known or suspected pancreatic cancer or pathologic lymphadenopathy.\n* Radiological diagnosis of IPMN with any of the following:\n\n  1. Main pancreatic duct dilation of \\>10 mm\n  2. Cytology with high grade dysplasia or \"suspicious for malignancy\"\n  3. Common bile duct obstruction causing jaundice\n  4. Septated cysts with \\> 4 compartments\n  5. Epithelial type mural nodules (\\> 2mm)\n  6. Lesions with thick wall\u002Fseptation (\\> 2mm)\n  7. High-grade communication with the main pancreatic duct\n  8. Previous aspiration failure due to excessive cyst fluid viscosity\n* Clinically significant laboratory abnormalities\n\n  1. INR \\>= 1.7\n  2. APTT \\> 80 secs\n  3. Platelet count \\\u003C 100 x 10E9\u002FL\n  4. ALT \\> 500 U\u002FL\n  5. Total bilirubin \\> 25 umol\u002FL\n* Evidence of pancreatitis within the last 6 months.\n* History of hypersensitivity to gemcitabine or paclitaxel.\n* Concurrent illness that may jeopardise the ability of the patient to safely undergo the procedures outlined in this protocol.\n* Any medical condition that would, at the discretion of the investigator, interfere with the completion of and\u002For participation in the protocol.\n* Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the trial protocol and follow-up schedule, including alcohol dependence or drug abuse.\n* Pregnancy, lactation, or inadequate contraception.",{"count":271,"type":20},20,[53],"The goal of this single-arm intervention trial is to determine the feasibility of implementing endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel for intraductal papillary mucinous neoplasms (IPMN) in two New Zealand tertiary interventional endoscopy centres.",[275],"Intraductal Papillary Mucinous Neoplasm of Pancreas","2025-04-21",{"date":278,"type":33},"2025-04-23",{"date":280,"type":20},"2025-05-31",{"date":282,"type":20},"2026-07-31",{"name":39,"class":40},2,{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":48,"sex":16,"minAge":293,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":51,"phases":296,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":71},"100580038","phase-3-nicotine-patch-plus-nicotine-mouth-spray-versus-nicotine-reduction-for-vaping-cessation-100580038","NCT06832098","Nicotine Patch Plus Nicotine Mouth Spray Versus Nicotine Reduction for Vaping Cessation","The New Zealand Quit Vaping Trial: Combination Nicotine Replacement Therapy Versus Nicotine Reduction.","EQUIT3","Inclusion Criteria:\n\n* Live in New Zealand.\n* Vape nicotine at least weekly (one or more days out of the past seven days).\n* Used to smoke (i.e. they have smoked tobacco regularly but not at all in the past six months) or have never smoked (i.e., they have never been a regular user of smoked tobacco, defined as less than 100 cigarettes in their lifetime).\n* Are aged ≥16 years.\n* Are motivated to quit vaping in the next eight weeks.\n* Are able to provide consent.\n* Have access to the internet via a computer or smart phone.\n* Are a registered patient at a New Zealand medical facility.\n\nExclusion Criteria:\n\n* They have another person in their household currently enrolled in the study.\n* They smoke tobacco currently or were a recent regular user of tobacco.\n* They are enrolled in another vaping cessation programme\u002Ftrial.\n* They self-report having had a serious cardiovascular event, or hospitalisation for a cardiovascular complaint, in the previous four weeks (e.g. stroke, myocardial infarction, unstable angina, cardiac arrhythmia, coronary artery bypass graft and angioplasty).\n* They self-report uncontrolled hypertension.\n* They have a strong preference to use\u002Fnot use NRT or nicotine tapering.\n* They are current users of smoking cessation pharmacotherapy (e.g. NRT, varenicline, cytisine, nortriptyline \\[including if it is used for a different indication\\], and amitriptyline \\[as it converts to nortriptyline\\].\n* They are currently enrolled in another vaping cessation programme\u002Ftrial.","16 Years",{"count":295,"type":20},774,[297],"PHASE3","This research focuses on maximizing the chances of successfully quitting vaping. A large, pragmatic community-based clinical trial is planned in New Zealand to build on existing evidence from previous vaping and smoking cessation research undertaken by the study team. The effectiveness of combination nicotine replacement therapy (NRT) compared to nicotine tapering on vaping abstinence has not yet been investigated, but both provide an opportunity to increase success with vaping cessation, especially when combined with written behavioural support to further boost quit rates.\n\nThe planned trial will test whether using combination NRT will help more New Zealanders to quit vaping long-term, compared with a vape nicotine tapering plan. Participants in both groups will also receive written vaping cessation behavioural support.",[300],"Vaping Cessation",[302,303,304,305,306,307,308,309],"Nicotine tapering","Pragmatic","Effectiveness","Vaping cessation","Nicotine Replacement Therapy","e-cigarette","nicotine mouth spray","nicotine patch","2025-03-29",{"date":312,"type":33},"2025-04-03",{"date":314,"type":33},"2025-03-25",{"date":316,"type":20},"2027-04-30",{"name":39,"class":40},{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":51,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":71},"100557476","the-5-fu-holter-study-100557476","NCT06538610","The 5-FU Holter Study","Feasibility Study of Ambulatory Holter Monitoring While Receiving Infusional Fluorouracil (5-FU) Chemotherapy","Inclusion Criteria:\n\n* Patients with diagnosis of gastrointestinal malignancy\n* Planned to receive either FOLFOX chemotherapy with any treatment intent\n* Aged ≥ 18 years at time of signing informed consent form\n\nExclusion Criteria:\n\n• ECG with left bundle branch block or left ventricular hypertrophy with strain",{"count":326,"type":20},10,[53],"To assess the feasibility of using ambulatory ECG monitoring (Holter monitor) for patients receiving 5-FU chemotherapy",[330],"Gastrointestinal Malignancy","2024-12-04",{"date":333,"type":33},"2024-12-09",{"date":335,"type":33},"2024-11-01",{"date":337,"type":20},"2026-01",{"name":39,"class":40},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":348,"conditions":349,"keywords":357,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":284},"100566930","an-observational-study-using-the-lumassure-device-in-participants-undergoing-assessment-of-skin-conditions-100566930","NCT06661577","An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions.","A Multi-Centre Observational Study For The Collection Of A Raman Spectral Database Using The LumAssure Device In Adult Participants Undergoing Dermatological Assessment Of Skin Conditions","Inclusion Criteria:\n\n* Able to provide informed consent\n* Male or female aged 18 years or over.\n* Willing to undergo a LumAssure device measurement on at least 1 skin condition\n* (For Standard of Care patients): are undergoing a skin examination and\u002For tissue excision by a qualified specialist\n* (For Healthy volunteers): are attending a skin check at a study clinic\n\nExclusion Criteria:\n\n* Tattoo on the skin condition to be measured\n* Skin conditions on or directly around the eye area",{"count":347,"type":20},3000,"This is an observational study in adult males and females utilising skin condition measurements using the LumAssure Raman device. Data will be used to determine accuracy under the ROC curve (AUCROC) of the LumAssure device for differentiating between benign and cancerous skin conditions. The measurements will provide data which will be used to establish spectral parameters for different skin conditions. Measurements will be benchmarked against diagnoses from medical specialists, and when available confirmed with histological data.\n\nThe main question it aims to answer is :\n\nWhat is the accuracy, in terms of the area under the ROC curve (AUCROC) of the LumAssure device for differentiating between benign skin conditions and skin cancers in adult males and females? Participants include males and females aged ≥18 years who are undergoing assessment of a skin condition (a lesion or rash) by a dermatologist, general practitioner, or plastic surgeon. Participants' attending the clinics will have their skin conditions examined by a clinician. The LumAssure device will then be used to measure Raman spectra of skin conditions and marked by the clinician. The Raman measurements will be benchmarked against skin condition assessment and, where available, diagnosis by a dermatologist, general practitioner, or a plastic surgeon, and for those lesions undergoing biopsy, confirmed with histology data.",[350,351,352,353,354,355,356],"Skin Cancers - Basal Cell Carcinoma","Skin Cancers - Squamous Cell Carcinoma","Melanoma of Skin","Inflammatory Dermatoses","Acral Melanoma","Benign Skin Nevus","Benign Skin Tumor",[358,359,360],"skin cancers","melanoma","diagnostic device","2024-10-24",{"date":363,"type":33},"2024-10-28",{"date":365,"type":20},"2024-12-13",{"date":367,"type":20},"2026-02-28",{"name":39,"class":40},""]